INDIVIOR PHARMACEUTICALS, INC.— Sankey Diagram
Quarterly mode · period ending 2025-12-31 · SEC EDGAR
ComparingFY2025 (Q4) vs FY2024 (Q4)
Revenue
$358M
↑+19.7% +$59Mvs FY2024 (Q4)
Gross Profit
$291M
↑+16.1% +$40Mvs FY2024 (Q4)
Operating Income
$81M
↑+76.1% +$35Mvs FY2024 (Q4)
Net Income
$81M
↑+285.7% +$60Mvs FY2024 (Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 (Q4) | FY2024 (Q4) |
|---|---|---|
| Revenue | $358M | $299M |
| COGS | $67M | $48M |
| Gross Profit | $291M | $251M |
| R&D | $21M | $31M |
| SG&A | $189M | $174M |
| D&A | $187K | $0 |
| Other OpEx | $0 | $0 |
| Operating Income | $81M | $46M |
| Interest Exp. | $0 | $8M |
| Other Non-Op | $0 | $0 |
| Pretax Income | $81M | $38M |
| Tax | $0 | $17M |
| Net Income | $81M | $21M |
QuarterCharts · SEC EDGAR data · INDV · Comparing FY2025 (Q4) vs FY2024 (Q4)